Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Bioxodes

News headline image
Bioxodes raises €5.5 million Series A extension to continue preparations for pivotal trial of breakthrough stroke candidate
From Bioxodes
Via GlobeNewswire
News headline image
Bioxodes presents BIOX-101 clinical data showing breakthrough potential for stroke in webcast with Prof Dr Robin Lemmens
From Bioxodes
Via GlobeNewswire
News headline image
Bioxodes appoints industry veteran Philippe Monteyne as chairman as it accelerates late-stage development of breakthrough stroke candidate
From Bioxodes
Via GlobeNewswire
News headline image
Bioxodes positive Phase 2a stroke data show breakthrough potential of innovative therapeutic candidate BIOX-101
From Bioxodes
Via GlobeNewswire
News headline image
Bioxodes announces positive Phase 2a interim data for BIOX-101 in intracerebral hemorrhagic stroke patients
From Bioxodes
Via GlobeNewswire
News headline image
Bioxodes obtains Orphan Drug Designation for hemorrhagic stroke therapeutic candidate in US and Europe
From Bioxodes
Via GlobeNewswire
News headline image
Bioxodes secures new funds to reach early 2025 milestones and pursue Series B financing
From Bioxodes
Via GlobeNewswire
News headline image
Bioxodes meets enrollment milestone in Phase 2a intracerebral hemorrhagic stroke trial
From Bioxodes
Via GlobeNewswire
News headline image
Bioxodes reports positive DMC meeting for BIOX-101 Phase 2a trial in intracerebral hemorrhagic stroke
From Bioxodes
Via GlobeNewswire
News headline image
Bioxodes meets first Phase 2a patient enrollment milestone with BIOX-101 in intracerebral hemorrhagic stroke
From Bioxodes
Via GlobeNewswire
News headline image
Bioxodes receives European Patent Office intention to grant patent, offering lead asset broad protection in thromboinflammation
From Bioxodes
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.